Vivos Therapeutics Inc <VVOS.OQ> expected to post a loss of 39 cents a share - Earnings Preview

• Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to show a rise in quarterly revenue when it reports results on March 26 (estimated) for the period ending December 31 2024

• The Littleton Colorado-based company is expected to report a 19.6% increase in revenue to $3.886 million from $3.25 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 39 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Vivos Therapeutics Inc is $6.30​, above​ its last closing price of $3.60. ​​​

This summary was machine generated March 24 at 11:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)